The antiestrogen endoxifen protects rat liver mitochondria from permeability transition pore opening and oxidative stress at concentrations that do not affect the phosphorylation efficiency

Toxicology and Applied Pharmacology

Volumn 267, Issue 1, 2013, Pages 104-112

  Ribeiro, Mariana P C ^a,b   Silva, Filomena S G ^a,b   Santos, Armanda E ^a,b   Santos, Maria S ^a,c   Custódio, José B A ^a,b  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Endoxifen; Mitochondria; Oxidative phosphorylation; Oxidative stress; Permeability transition; Tamoxifen

Indexed keywords

ADENOSINE DIPHOSPHATE; CALCIUM ION; CYCLOSPORIN A; ENDOXIFEN; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; OLIGOMYCIN; PROTON; TAMOXIFEN; XENOBIOTIC AGENT;

ANIMAL EXPERIMENT; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; LIGHT SCATTERING; LIVER MITOCHONDRION; LIVER PROTECTION; MEMBRANE PERMEABILITY; MITOCHONDRIAL MEMBRANE POTENTIAL; NONHUMAN; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PROTEIN PHOSPHORYLATION; RAT;

ANIMALS; ESTROGEN ANTAGONISTS; FEMALE; INTRACELLULAR MEMBRANES; MALE; MITOCHONDRIA, LIVER; OXIDATIVE STRESS; PERMEABILITY; PHOSPHORYLATION; PORINS; PROTECTIVE AGENTS; RATS; RATS, WISTAR; TAMOXIFEN;

RATTUS;

EID: 84872252817     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2012.12.012     Document Type: Article

References (50)

1. Ahmad A., Shahabuddin S., Sheikh S., Kale P., Krishnappa M., Rane R.C., Ahmad I. Endoxifen, a new cornerstone of breast cancer therapy: demonstration of safety, tolerability, and systemic bioavailability in healthy human subjects. Clin. Pharmacol. Ther. 2010, 88:814-817.
2. Ahmad A., Ali S.M., Ahmad M.U., Sheikh S., Ahmad I. Orally administered Endoxifen is a new therapeutic agent for breast cancer. Breast Cancer Res. Treat. 2010, 122:579-584.
3. Begriche K., Igoudjil A., Pessayre D., Fromenty B. Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion 2006, 6:1-28.
4. Bernardi P., von Stockum S. The permeability transition pore as a Ca(2+) release channel: new answers to an old question. Cell Calcium 2012, (http://dx.doi.org/10.1016/j.ceca.2012.03.004).
5. Borges S., Desta Z., Li L., Skaar T.C., Ward B.A., Nguyen A., Jin Y., Storniolo A.M., Nikoloff D.M., Wu L., Hillman G., Hayes D.F., Stearns V., Flockhart D.A. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin. Pharmacol. Ther. 2006, 80:61-74.
6. Cardoso C.M., Custódio J.B., Almeida L.M., Moreno A.J. Mechanisms of the deleterious effects of tamoxifen on mitochondrial respiration rate and phosphorylation efficiency. Toxicol. Appl. Pharmacol. 2001, 176:145-152.
7. Cardoso C.M., Moreno A.J., Almeida L.M., Custódio J.B. 4-Hydroxytamoxifen induces slight uncoupling of mitochondrial oxidative phosphorylation system in relation to the deleterious effects of tamoxifen. Toxicology 2002, 179:221-232.
8. Cardoso C.M., Almeida L.M., Custódio J.B. 4-Hydroxytamoxifen is a potent inhibitor of the mitochondrial permeability transition. Mitochondrion 2002, 1:485-495.
9. Cardoso C.M., Moreno A.J., Almeida L.M., Custódio J.B. Comparison of the changes in adenine nucleotides of rat liver mitochondria induced by tamoxifen and 4-hydroxytamoxifen. Toxicol. In Vitro 2003, 17:663-670.
10. Cardoso C.M., Almeida L.M., Custódio J.B. Protection of tamoxifen against oxidation of mitochondrial thiols and NAD(P)H underlying the permeability transition induced by prooxidants. Chem. Biol. Interact. 2004, 148:149-161.
11. Ching C.K., Smith P.G., Long R.G. Tamoxifen associated hepatocellular damage and agranulocytosis. Lancet 1992, 339:940.
12. Cruz Silva M.M., Madeira V.M., Almeida L.M., Custódio J.B. Hemolysis of human erythrocytes induced by tamoxifen is related to disruption of membrane structure. Biochim. Biophys. Acta 2000, 1464:49-61.
13. Cruz Silva M.M., Madeira V.M., Almeida L.M., Custódio J.B. Hydroxytamoxifen interaction with human erythrocyte membrane and induction of permeabilization and subsequent hemolysis. Toxicol. In Vitro 2001, 15:615-622.
14. Custódio J.B., Almeida L.M., Madeira V.M. A reliable and rapid procedure to estimate drug partitioning in biomembranes. Biochem. Biophys. Res. Commun. 1991, 176:1079-1085.
15. Custódio J.B., Almeida L.M., Madeira V.M. The active metabolite hydroxytamoxifen of the anticancer drug tamoxifen induces structural changes in membranes. Biochim. Biophys. Acta 1993, 1153:308-314.
16. Custódio J.B., Almeida L.M., Madeira V.M. The anticancer drug tamoxifen induces changes in the physical properties of model and native membranes. Biochim. Biophys. Acta 1993, 1150:123-129.
17. Custódio J.B., Dinis T.C., Almeida L.M., Madeira V.M. Tamoxifen and hydroxytamoxifen as intramembraneous inhibitors of lipid peroxidation. Evidence for peroxyl radical scavenging activity. Biochem. Pharmacol. 1994, 47:1989-1998.
18. 2+ and inorganic phosphate. Toxicol. Appl. Pharmacol. 1998, 152:10-17.
19. DeLeve L.D. Hormones. Cancer chemotherapy. Drug-induced Liver Disease 2007, 651-652. Informa Healthcare USA, New York. N. Kaplowitz, L.D. DeLeve (Eds.).
20. Farrell G.C. Drugs and steatohepatitis. Semin. Liver Dis. 2002, 22:185-194.
21. Halestrap A.P., Woodfield K.Y., Connern C.P. Oxidative stress, thiol reagents, and membrane potential modulate the mitochondrial permeability transition by affecting nucleotide binding to the adenine nucleotide translocase. J. Biol. Chem. 1997, 272:3346-3354.
22. Henry N.L., Rae J.M., Li L., Azzouz F., Skaar T.C., Desta Z., Sikora M.J., Philips S., Nguyen A.T., Storniolo A.M., Hayes D.F., Flockhart D.A., Stearns V. Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort. Breast Cancer Res. Treat. 2009, 117:571-575.
23. Hernández-Esquivel L., Natalia-Pavón, Zazueta C., García N., Correa F., Chávez E. Protective action of tamoxifen on carboxyatractyloside-induced mitochondrial permeability transition. Life Sci. 2011, 88:681-687.
24. Ingle J.N. Pharmacogenomics of tamoxifen and aromatase inhibitors. Cancer 2008, 112(3 Suppl.):695-699.
25. Ingle J.N., Suman V.J., Johnson P.A., Krook J.E., Mailliard J.A., Wheeler R.H., Loprinzi C.L., Perez E.A., Jordan V.C., Dowsett M. Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer. Clin. Cancer Res. 1999, 5:1642-1649.
26. Javadov S., Karmazyn M., Escobales N. Mitochondrial permeability transition pore opening as a promising therapeutic target in cardiac diseases. J. Pharmacol. Exp. Ther. 2009, 330:670-678.
27. Kazanci N., Severcan F. Concentration dependent different action of tamoxifen on membrane fluidity. Biosci. Rep. 2007, 27:247-255.
28. Kelly C.M., Juurlink D.N., Gomes T., Duong-Hua M., Pritchard K.I., Austin P.C., Paszat L.F. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ 2010, 340:c693.
29. Kiyotani K., Mushiroda T., Nakamura Y., Zembutsu H. Pharmacogenomics of tamoxifen: roles of drug metabolizing enzymes and transporters. Drug Metab. Pharmacokinet. 2012, 27:122-131.
30. Kushnareva Y.E., Sokolove P.M. Prooxidants open both the mitochondrial permeability transition pore and a low-conductance channel in the inner mitochondrial membrane. Arch. Biochem. Biophys. 2000, 376:377-388.
31. Labbe G., Pessayre D., Fromenty B. Drug-induced liver injury through mitochondrial dysfunction: mechanisms and detection during preclinical safety studies. Fundam. Clin. Pharmacol. 2008, 22:335-353.
32. Lammers L.A., Mathijssen R.H.J., van Gelder T., Bijl M.J., de Graan A.-J.M., Seynaeve C., van Fessem M.A., Berns E.M., Vulto A.G., van Schaik R.H.N. The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer. Br. J. Cancer 2010, 103:765-777.
33. Lee K.H., Ward B.A., Desta Z., Flockhart D.A., Jones D.R. Quantification of tamoxifen and three metabolites in plasma by high-performance liquid chromatography with fluorescence detection: application to a clinical trial. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 2003, 791:245-253.
34. Leung A.W., Varanyuwatana P., Halestrap A.P. The mitochondrial phosphate carrier interacts with cyclophilin D and may play a key role in the permeability transition. J. Biol. Chem. 2008, 283:26312-26323.
35. Lien E.A., Wester K., Lonning P.E., Solheim E., Ueland P.M. Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients. Br. J. Cancer 1991, 63:641-645.
36. Liu C.L., Yang T.L. Sequential changes in serum triglyceride levels during adjuvant tamoxifen therapy in breast cancer patients and the effect of dose reduction. Breast Cancer Res. Treat. 2003, 79:11-16.
37. Lu W.J., Desta Z., Flockhart D.A. Tamoxifen metabolites as active inhibitors of aromatase in the treatment of breast cancer. Breast Cancer Res. Treat. 2012, 131:473-481.
38. Moreira P.I., Custódio J., Moreno A., Oliveira C.R., Santos M.S. Tamoxifen and estradiol interact with the flavin mononucleotide site of complex I leading to mitochondrial failure. J. Biol. Chem. 2006, 281:10143-10152.
39. Moreira P.I., Custódio J.B., Nunes E., Moreno A., Seiça R., Oliveira C.R., Santos M.S. Estradiol affects liver mitochondrial function in ovariectomized and tamoxifen-treated ovariectomized female rats. Toxicol. Appl. Pharmacol. 2007, 221:102-110.
40. Oien K.A., Moffat D., Curry G.W., Dickson J., Habeshaw T., Mills P.R., MacSween R.N. Cirrhosis with steatohepatitis after adjuvant tamoxifen. Lancet 1999, 353:36-37.
41. Rolo A.P., Teodoro J.S., Palmeira C.M. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radic. Biol. Med. 2012, 52:59-69.
42. Sakhri J., Ben Salem C., Harbi H., Fathallah N., Ltaief R. Severe acute pancreatitis due to tamoxifen-induced hypertriglyceridemia with positive rechallenge. JOP 2010, 11:382-384.
43. Santos M.S., Santos D.L., Palmeira C.M., Seiça R., Moreno A.J., Oliveira C.R. Brain and liver mitochondria isolated from diabetic Goto-Kakizaki rats show different susceptibility to induced oxidative stress. Diabetes Metab. Res. Rev. 2001, 17:223-230.
44. Saphner T., Triest-Robertson S., Li H., Holzman P. The association of nonalcoholic steatohepatitis and tamoxifen in patients with breast cancer. Cancer 2009, 115:3189-3195.
45. Storen E.C., Hay J.E., Kaur J., Zahasky K., Hartmann L. Tamoxifen-induced submassive hepatic necrosis. Cancer J. 2000, 6:58-60.
46. Thompson A.M., Johnson A., Quinlan P., Hillman G., Fontecha M., Bray S.E., Purdie C.A., Jordan L.B., Ferraldeschi R., Latif A., Hadfield K.D., Clarke R.B., Ashcroft L., Evans D.G., Howell A., Nikoloff M., Lawrence J., Newman W.G. Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy. Breast Cancer Res. Treat. 2011, 125:279-287.
47. Vignais P.V. Molecular and physiological aspects of adenine nucleotide transport in mitochondria. Biochim. Biophys. Acta 1976, 456:1-38.
48. Wallace K.B., Starkov A.A. Mitochondrial targets of drug toxicity. Annu. Rev. Pharmacol. Toxicol. 2000, 40:353-388.
49. Wu X., Hawse J.R., Subramaniam M., Goetz M.P., Ingle J.N., Spelsberg T.C. The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells. Cancer Res. 2009, 69:1722-1727.
50. Zoratti M., Szabò I. The mitochondrial permeability transition. Biochim. Biophys. Acta 1995, 1241:139-176.